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Infection by Toxoplasma gondii affects around one-third of world population and the
treatment for patients presenting toxoplasmosis clinically manifested disease is mainly
based by a combination of sulfadiazine, pyrimethamine, and folinic acid. However, this
therapeutic protocol is significantly toxic, causing relevant dose-related bone marrow
damage. Thus, it is necessary to improve new approaches to investigate the usefulness
of more effective and non-toxic agents for treatment of patients with toxoplasmosis.
It has been described that lectins from plants can control parasite infections, when
used as immunological adjuvants in vaccination procedures. This type of lectins, such
as ArtinM and ScLL is able to induce immunostimulatory activities, including efficient
immune response against parasites. The present study aimed to evaluate the potential
immunostimulatory effect of ScLL and ArtinM for treatment of T. gondii infection during
acute phase, considering that there is no study in the literature accomplishing this
issue. For this purpose, bone marrow-derived macrophages (BMDMs) were treated
with different concentrations from each lectin to determine the maximum concentration
without or with lowest cytotoxic effect. After, it was also measured the cytokine
levels produced by these cells when stimulated by the selected concentrations of
lectins. We found that ScLL showed high capacity to induce of pro-inflammatory
cytokine production, while ArtinM was able to induce especially an anti-inflammatory
cytokines production. Furthermore, both lectins were able to increase NO levels. Next,
we evaluated the treatment effect of ScLL and ArtinM in C57BL/6 mice infected by
ME49 strain from T. gondii. The animals were infected and treated with ScLL, ArtinM,
ArtinM plus ScLL, or sulfadiazine, and the following parameters analyzed: Cytokines
production, brain parasite burden and survival rates. Our results demonstrated that
the ScLL or ScLL plus ArtinM treatment induced production of pro-inflammatory and
anti-inflammatory cytokines, showing differential but complementary profiles. Moreover,
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when compared with non-treated mice, the parasite burden was significantly lower
and survival rates higher in mice treated with ScLL or ScLL plus ArtinM, similarly with
sulfadiazine treatment. In conclusion, the results demonstrated the suitable potential
immunotherapeutic effect of ScLL and ArtinM lectins to control acute toxoplasmosis in
this experimental murine model.
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INTRODUCTION
Toxoplasma gondii is an obligate intracellular apicomplexan
parasite, and it is the etiologic agent of toxoplasmosis, being able
to infect virtually all warm blood vertebrates, including human
beings (Dubey et al., 1998, 2012; Tenter et al., 2000; Samra et al.,
2007; Lopes et al., 2014).
This infection is asymptomatic and well tolerated for the
majority of the infected people, but it can cause severe disease
and high rates of morbidity and mortality for some groups of
patients, as the immunocompromised individuals, such as for
AIDS patients (Enzensberger et al., 1985; Bal et al., 2014), as well
as when it occurs during pregnancy, because the parasite can
cross placenta and cause congenital toxoplasmosis (Jones et al.,
2001; AdamsWaldorf and McAdams, 2013). Thus, the treatment
of toxoplasmosis is required for these patients presenting high
risk of severe tissue damage (Vijayalaxmi and Vishalakshi, 2000;
Montoya and Liesenfeld, 2004; Elsheikha, 2008; Kaye, 2011;
Rodriguez and Szajnman, 2012; Blader et al., 2015). If fetal
infection is confirmed, the mother should be treated with a
combination of sulfadiazine, pyrimethamine, and folinic acid
(Montoya and Remington, 2008). Even though sulfadiazine and
pyrimethamine are widely used, these drugs are highly toxic and
may cause severe adverse effects (Montoya and Remington, 2008;
Kaye, 2011). In fact, these drugs may result in bone marrow
toxicity, including megaloblastic anemia or pancytopenia, which
may be reversible or preventable in some patients with folate
supplementation (Mori et al., 2011). In addition to cause these
severe side effects, these drugs might not be able to reduce
the parasitism, as T. gondii has shown to present resistance to
sulfadiazine (Meneceur et al., 2008; Doliwa et al., 2013; Oliveira
et al., 2016).
The immune response against T. gondii involves complex
mechanisms of innate and adaptive immunity. A Th1-type
immune response is observed during acute infection, involving
synthesis of cytokines, as IFN-γ and IL-12 (Gazzinelli et al., 1994;
Lang et al., 2007). Given that modulated immunity is critical to
control the parasite burden (Dupont et al., 2012), the induction of
an appropriate immune response just after infection constitutes
an remarkable alternative for toxoplasmosis treatment.
It has been described in the literature that lectins from plants,
such as ArtinM from seeds of jackfruit (Artocarpus integrifolia)
and ScLL from the latex of the Euphorbiaceae Synadenium
carinatum, when used as immunological adjuvants in vaccination
protocols, can control parasite infections caused by Leishmania
major, Leishmania amazonensis orNeospora caninnun (Panunto-
Castelo et al., 2001; Teixeira et al., 2006; Afonso-Cardoso et al.,
2007; Toledo et al., 2009; Cardoso et al., 2011).
Considering that it is necessary to improve new approaches to
investigate the usefulness of more effective and non-toxic agents
for treatment of patients with toxoplasmosis, in addition to the
fact that ScLL and ArtinM have been previously used only in
vaccination protocols for parasitic infections, the major aim of
the present study was to evaluate whether these lectins could be
also applicable as therapeutic agents to avoid the tissue damages
occurring in consequence of T. gondii infection.
MATERIALS AND METHODS
Animals
Female inbred C57BL/6 mice, aging 8–10 weeks, were obtained
from Federal University of Uberlândia (UFU), Uberlândia, MG,
Brazil. Animals were maintained under standard conditions in
the Animal Facility from this Institution. All procedures were
conducted in accordance with the guidelines for animal ethics
and the study received approval of the Ethics Committee for
Animal Experimentation of the Institution (CEUA-UFU), under
protocol # 058/14.
Parasites
Brain cysts from ME49 strain of T. gondii were obtained from
Calomys callosus, as previously described (Ferro et al., 2002).
Briefly, animals were infected for 45 days and their brains
were removed, washed in PBS and homogenized. T. gondii cyst
numbers were counted by light microscopy and volumes of 200
µL of PBS containing 10 cysts were administered to mice to carry
out the experimental procedures.
Lectins from Synadenium carinatum Latex
(ScLL) and Artocarpus heterophyllus
Seeds (ArtinM)
Specimens from S. carinatum were harvested in Uberlândia,
MG, Brazil. ScLL was obtained as previously described (Souza
et al., 2005), with some modifications. Briefly, proteins were
extracted from the fresh plant latex by gentle shaking with
distilled water, for 24 h, at 4◦C. The mixture was centrifuged
for 10 min at 10,000 g, filtered on 0.45 µm membranes and
frozen at −20◦C for 48 h. After being defrosted and filtered
again, the extract was submitted to affinity chromatography using
immobilized D-galactose column on agarose (Pierce, Rockford,
USA). The D-galactose-binding lectin (ScLL) was eluted with
0.2 M D-galactose (Sigma Chemical Co., St Louis, USA) in BBS,
concentrated, and dialyzed using Amicon R© Ultra-Filters 40 kDa
(Merck, Göttingen, Germany). The protein concentration was
determined (Bradford, 1976) and ScLL purity was confirmed
by sodium dodecyl sulfate polyacrylamide gel electrophoresis
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(SDS-PAGE) stained with Coomassie Blue (Laemmli, 1970). ScLL
aliquots were stored at −20◦C until be used in the experimental
procedures.
The D-mannose-binding ArtinM lectin extracted from
A. heterophylluswas obtained from seeds of jackfruit and purified
by sugar affinity chromatography, as previously described (Bunn-
Moreno and Campos-Neto, 1981; Roque-Barreira et al., 1986).
In vitro Assays
Bone Marrow-Derived Macrophages (BMDMs)
Bone marrow-derived macrophages (BMDMs) were obtained
from C57BL/6 mice as previously described (Marim et al., 2010).
Briefly, the femurs from mice (n = 2) were removed and washed
with sterile PBS in Petri dish. The cell suspensions were collected,
filtered, and centrifuged for 10 min at 400 g. The pellets were
suspended in RPMI-1640media containing 15% of LCCM (L-cell
Conditioned Media) from L929 cell culture and incubated for 24
h. Cells were washed again and suspended in medium containing
2% SBF (serum bovine fetal). Viable cells were counted in a
Neubauer chamber, using the Trypan blue exclusion vital stain.
Cytotoxicity Assay—(MTT)
To assess the cytotoxic effect on macrophages treated with
different concentrations of ScLL or ArtinM lectins, we performed
the tetrazolium salt (MTT) colorimetric assay (Mosmann, 1983).
Cells were treated with ScLL (50.0; 16.6; 5.5; 1.8; 0.61; 0.20;
and 0.06 µg/mL) or ArtinM (1.0; 0.33; 0.11; 0.037; 0.012; 0.004;
0.00013; and 0.00004µg/mL) and incubated at 37◦C and 5%CO2
for 24 h before being analyzed.
Cytokines (IL-10, IL-12p40) and NO Measurements
BMDMs were cultured and stimulated with ScLL (50.0, 16.6,
5.5, 1.8, 0.61, 0.20, and 0.06 µg/mL) or ArtinM (1.0, 0.33,
0.11 µg/mL). Cells stimulated by LPS (1 µg/mL) or medium
alone were included in all experiments, as positive and negative
controls, respectively. Cell supernatants were collected and stored
at –70◦C for detection of IL-10, IL-12p40 and nitrite. Cytokine
measurements were performed by sandwich ELISA according to
manufacturer’s instructions (R&D Systems, Minneapolis, MN).
The limit of detection was 31 pg/mL for all cytokines. Nitrite was
measured by Griess Reaction (Green et al., 1982).
Experimental Infection and Treatment
Mice (n = 45) were orally infected with 10 cysts of T. gondii
ME49 strain and treated with sulfadiazine or lectins. For survival
analysis, 25 animals were used, while 20 animals were used for
cytokine measurement levels. Thirty days after infection, the
surviving animals from both experiments were euthanized and
their brains collected for determination of the parasite burden by
Real-time PCR.
Survival Analysis
Five groups (n = 5) of infected and treated mice were chosen
for survival analysis. One group was treated with sulfadiazine
(250mg diluted in 400 mL of drinking water given to the animals
for 6 days), whereas four groups were treated for 6 days, at
1-day intervals, intraperitoneally, according with the following
preparations: 50 µg of ScLL; 50 µg of ScLL plus 1 µg of ArtinM;
1 µg ArtinM; or PBS only. These lectin concentrations were
chosen based on previous studies (Cardoso et al., 2011, 2012).
Thirty days after infection the surviving animals were euthanized
and their brains collected to determine the rates of parasitism
burden.
Measurement of Serum Levels of Cytokines
The production of cytokines was assessed in blood samples
from infected and treated mice, as well as before treatment
and infection and at the end of the treatments, i.e., 7 days
after the infection. The serum samples were stored at −70◦C
until being analyzed for measurement of IL-2, IL-4, IL-6, IL-
10, IL-17, IFN-γ, and TNF cytokines by Cytometric Bead
Array (CBA) (BD Bioscience, San Jose, USA), according to the
manufacturer’s instructions. Samples were analyzed under BD
flow cytometry (FACSCanto II; BD Company, San Diego, USA),
and data were analyzed by using FlowJo data analysis software
(FlowJo, LLC, Ashland, USA). The results were expressed as
mean concentration pg/mL.
Determination of Parasite Burden in the
Brain Tissues
Parasite burden was determined in the brain tissues by
quantitative real-time polymerase chain reaction (qPCR). Total
DNA was extracted using Proteinase K (Promega Co., Madison,
WI, USA), as described by Miller et al. (1988). Total DNA
was quantified by UV spectrophotometry at 260 nm (ND1000
Spectrophotometer; NanoDrop Technologies, Wilmington,
USA). Real-time PCR was performed using the 7500 Real-time
PCR System (Applied Biosystems, Foster City, USA) and SYBR R©
Green was used to detect fluorescence in PCR reaction, according
to the manufacturer’s instructions (Invitrogen, San Francisco,
USA). The reaction conditions followed the protocols using
primer pairs, forward, 5′-CACAGAAG GGACAGAAGT-3′ and
reverse, 5′-TCGCCTTCATCTAC AGTC-3′) for amplification of
T. gondii, as previously described (Homan et al., 2000; Wahab
et al., 2010).
Statistical Analysis
The data were analyzed using GraphPad Prism 6.0 software
package (GraphPad Software Inc., San Diego, USA). Differences
among experimental and control groups were analyzed using
One-way ANOVA with Tukey’s multiple comparison post-test.
Data were expressed as mean ± standard deviation (SD). The
Kaplan-Meier method was applied to estimate the percentage
of mice surviving at each time point after infection and
survival curves were compared using the Log-rank Mantel-
Cox test. Values of P < 0.05 were considered statistically
significant.
RESULTS
BMDM Viability after Treatment with ScLL
or ArtinM
It was observed a dose-dependent cytotoxicity in BMDM treated
with ScLL. These cells treated with higher concentration of
ScLL (50 µg/mL) showed less than 50% of viability, whereas
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the total number of live cells was significantly increased when
the ScLL concentrations were reduced, showing viability rates
higher than 80% for doses equal or lower than 5.5 µg/mL the
(Figure 1A). In contrast, for ArtinM, the viability rates were
higher than 90% even at the higher concentration of 1 µg/mL
(Figure 1B).
Cytokines Production in BMDM under
ScLL or ArtinM Treatment
ScLL and ArtinM were able to induce the cytokines production
by BMDM (Figure 2). Cells treated with ScLL in concentrations
of 1.8; 0.61; or 0.20 µg/mL, it was observed strong IL-12
production, in similar levels to that induced by LPS stimulus
(Figure 2A). On the other hand, ScLL treatment was not able
to induce IL-10 production in this cell suspension (Figure 2B).
Regarding cells treated with ArtinM, it was found that this lectin
was able to stimulate IL-12 production, and the concentration
of 0.11 µg/mL induced the higher level of this cytokine,
FIGURE 1 | Cell viability determined by MTT assay in murine bone
marrow-derived macrophages (BMDMs), treated with ScLL (A) or
ArtinM (B) in several concentrations, ranging from 0.06 to 50 µg/ml or from
0.00004 to 1 µg/ml of ScLL or ArtinM, respectively. The cell suspensions were
cultured in RPMI-1640 medium and the data are representative of one from
three independent experiments. *P < 0.05.
achieving values similar to the LPS stimulus (Figure 2C). In
addition, ArtinM was able to induce IL-10 production in a dose-
dependent manner, achieving the highest level at 1.0 µg/mL
(Figure 2D).
Nitrite Production in BMDM Treated with
ScLL or ArtinM
Nitrite concentration was measured in macrophages treated with
ScLL or ArtinM, as an indicator of NO production. It was
observed that both ScLL and ArtinM were able to stimulate NO
production, being the higher level obtained in a concentration
of 1.8 µg/mL for ScLL, while the concentrations of 1 and 0.33
µg/mL of ArtinMwere equally able to induce higher levels of NO
production (Figure 3).
Cytokines Production by T. gondii-Infected
C57BL/6 Mice Treated with ScLL and/or
ArtinM Lectins
Given the efficiency of both lectins to stimulate cytokines
production in BMDM, it was investigated whether ScLL and/or
ArtinM treatments could be able to induce cytokines production
by C57BL/6 infected mice. Analyses of cytokine levels showed
that the treatment protocols with ScLL and/or ArtinM, consisting
of six doses of 50 µg of ScLL, or six doses of 50 µg of ScLL
plus 1µg of ArtinM, increased significantly the concentrations of
Th1, Th2, and Th17 cytokines when compared with non-treated
or sulfadiazine-treated animals (Figure 4). However, a different
profile concerning cytokines production was observed when the
animals were treated with different lectin combinations. It was
observed an induction higher of pro-inflammatory response in
ScLL treated animals group compared to the ScLL plus ArtinM
group. Indeed, IL-2, IFN-γ, and IL-6 production by infected
and treated mice with ScLL was higher in comparison with
ScLL plus ArtinM, as well as with sulfadiazine or non-treated
infected controls (PBS) (P < 0.05) (Figures 4A,C,E). In contrast,
ArtinM plus ScLL treatment induces higher levels of regulatory
cytokines with a significant increase of IL-4, IL-10, and IL-17
in relation to others groups (P < 0.005) (Figures 4B,D,G). No
significant difference in TNF production was observed among
the treatments with lectins or sulfadiazine (Figure 4F). ScLL
plus ArtinM demonstrated better balance of Th1/Th2 type of
immunity response.
Parasite Burden in C57BL/6 Mice Infected
by T. gondii and Treat with ScLL and/or
ArtinM Lectins
Parasite burden was examined in the brain tissues of the
animals submitted to the different experimental procedures.
As shown in Figure 5, it was observed that the treatments
with either ScLL or ArtinM plus ScLL significantly
reduced the parasite load in the central nervous system
compared to infected but non-treated group (P < 0.05). In
addition, it was not observed significant differences of T.
gondii-DNA levels among the groups receiving lectins or
sulfadiazine treatments, suggesting the ScLL and ArtinM
could indeed reduce T. gondii burden to the central nervous
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FIGURE 2 | Cytokine measurements in supernatants from bone marrow-derived macrophages (BMDMs) cultures after 48 h of stimulation with
different concentrations of ScLL or ArtinM. Medium alone (RPMI) or LPS (1µg/mL) were included in all experiments, as negative and positive controls,
respectively. Levels of IL-12 (A) and (C) and IL-10 (B) and (D) were determined by immunoenzymatic assay ELISA. Results are expressed as mean ± SD of cytokine
levels in pg/mL. *Statistically significant in relation to the control (RPMI-1640). (ANOVA and Tukey’s multiple comparison post-test; P < 0.05).
system with the effectiveness comparable to the traditional
chemotherapy.
Survival Rates of C57BL/6 Mice Infected by
T. gondii and Treated with ScLL and/or
ArtinM Lectins
To certify whether the lectins treatments may interfere in
the survival of C57BL/6 mice infected by T. gondii, when
comparing to the groups of animals non-treated or submitted
to chemotherapy, it was determined the survival rates 30-day
post-infection. As shown in Figure 6, the animals submitted to
the experimental treatment with lectins presented higher survival
rates than the infected but non-treated mice. Interestingly,
treatment with ScLL alone ensured a 100% survival of the
animals, equal the survival rate observed to those animals
submitted to the sulfadiazine treatment (Figure 6). Also, for the
group treated with ScLL plus ArtinM, the survival rate was 80%,
while the survival rate was 60% for the group of mice treated with
ArtinM alone. The infected but non-treated group had the lowest
survival rate of 20% (Figure 6), which was significantly lower
than the rates determined to groups treated with ScLL, ScLL plus
ArtinM or sulfadiazine (P < 0.05).
DISCUSSION
The strategies for toxoplasmosis treatment still show serious
limitations, particularly due to the high degree of toxicity that
has been associated with the current chemotherapy (Yeo et al.,
2016). Also, the possibility to occur parasite drug resistance
is an additional drawback to treat this disease based only on
chemotherapy (Hui et al., 2015). Due the immunostimulatory
effect of plant lectins, studies have been developed to implement
of vaccination protocols using new agents to stimulate the
immune system, as ScLL and ArtinM lectins extracted from
plants (Cardoso et al., 2011, 2012; Souza et al., 2013). However,
there is no previous study analyzing the therapeutic use of ScLL
and ArtinM against T. gondii infection.
The association of sulfadiazine with pyrimethamine
constitutes a protocol of treatment extensively used for
toxoplasmosis, considering that it has been demonstrated to
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FIGURE 3 | Nitric oxide production in supernatants from bone
marrow-derived macrophages (BMDMs) cultures after 48 h of
stimulation with different concentrations of ScLL or ArtinM and LPS (1
µg/mL). Cells were stimulated with ScLL (50; 16.6; 5.5; 1.8; 0.61; 0.20; and
0.06 µg/mL) or ArtinM (1; 0.33 and 0.11 µg/mL). Nitrite concentration
measured by Griess Reaction. The data are representative of one from three
independent experiments in triplicate for each condition. *Statistically
significant in relation to the control (RPMI-1640). (ANOVA and Tukey’s multiple
comparison post-test; P < 0.05).
be highly effective against T. gondii tachyzoites, but it may
cause severe hematological side effects, among other type of
toxicities (Bosch-Driessen et al., 2002; Chêne and Thiébaut,
2009; Andrews et al., 2014). Previous in vitro and in vivo
studies showed ScLL and ArtinM can be safely administered on
murine models (Panunto-Castelo et al., 2001; Afonso-Cardoso
et al., 2007; Cardoso et al., 2012). Furthermore, in vivo models
demonstrated that ScLL presents no cytotoxic activity against
J774 cells or peritoneal murine macrophages (Souza et al.,
2005). In the present study, it was demonstrated that BMDM
presented high rates of viability when treated with appropriate
concentrations of ScLL and ArtinM lectins. Considering this
framework, it is becoming very clear in the literature in last years
that the beneficial effects of the lectins transcend the problems of
the any potential side effect that could exist. Thus, the original
use of lectins in vaccination protocols has been expanded to
other applications. Hence, besides its use as therapeutic agents
in infectious and parasitic diseases, lectins have been applied
as new potential antineoplastic agents targeting apoptosis,
autophagy, and anti-angiogenesis in preclinical or clinical trials
for cancer therapeutics, and in neurodegenerative disorders, as
well (Alegre-Maller et al., 2014; Bogoeva et al., 2014; Aminou
et al., 2016; Barbosa-Lorenzi et al., 2016; Dar et al., 2016; Freitas
et al., 2016; Ricci-Azevedo et al., 2016).
The role of cytokines in the immune response againstT. gondii
is well known and it has been extensively demonstrated that the
regulation on Th1 pattern is necessary to control inflammatory
damage on tissues (Gazzinelli et al., 1994, 1996; Lang et al.,
2007). T. gondii control requires a fine-tuning induction of pro-
inflammatory and anti-inflammatory cytokines, such as IL-12,
IFN-γ, and IL-10 (Gazzinelli et al., 1991, 1996), but the tachyzoite
stage of the parasite is able to subvert the immune response,
being able, for instance, to blockade NF-κB nuclear translocation
and actively interfere in the IL-12 production (Yarovinsky, 2014;
Kim et al., 2016). Previous studies have been shown the ability
of ScLL and ArtinM to induce the production of cytokines,
when used as immunological adjuvants in vaccination protocols
(Cardoso et al., 2011, 2012). In fact, when these lectins are used
in murine models, they lead to the production of Th1, as well
as Th2 cytokines, and these effects are important to avoid the
deleterious consequences of unbalanced inflammatory cytokine
production (Cardoso et al., 2011, 2012). In the present study,
it was demonstrated that ScLL could stimulate in vitro IL-12
production by macrophages, but not IL-10, corresponding to an
induction of Th1 pattern immune response, which is necessary,
but not sufficient, to control T. gondii infection. However, for
ArtinM-stimulated macrophages, it was observed the production
of both IL-10 and IL-12. Interestingly, we also observed that the
lowest ArtinM dose resulted in the highest IL-10 production.
Nitric oxide produced by macrophages has been
demonstrated to be involved in anti-parasitic effects against
various protozoa parasites, as well as in pathogenesis, including
during T. gondii infection (Dincel and Atmaca, 2016). In the
present study, it was observed that NO levels increased in
macrophages stimulated in vitro with both ScLL and ArtinM.
It has been described in murine models that, when the animals
undergo the acute stage of infection by T. gondii, the NO
production contributes to the tachyzoite-bradyzoite stage
conversion (Ihara and Nishikawa, 2014). Our data showed that
the non-toxic doses of ScLL as ArtinM are able to stimulate nitric
oxide production by macrophages, which may be a relevant
event to decrease T. gondii replication.
In the present study, it was established an intraperitoneal
treatment protocol for toxoplasmosis, considering the results
previously described (Cardoso et al., 2011, 2012). Once high
concentration of ScLL showed cytotoxicity, it was evaluated
different doses of this lectin in mice to determine the occurrence
of side effects, as lethality test in mice. For this purpose, the
animals received six doses of PBS or ScLL (50, 20, 10, and 5
µg). The animals were observed during 30 days for the pattern of
morbidity (temperature, weight loss, mobility in the cage) and at
the end of that period all the treated animals showed no alteration
of their physical conditions (Data not shown).
Next, we investigated the capacity of the ScLL and ScLL plus
ArtinM to increase cytokine production in infected animals.
It was observed in the groups of animals treated with ScLL
alone or with ScLL plus ArtinM increased levels of both
pro-inflammatory and anti-inflammatory cytokines, showing
differential, but complementary profiles. Immunostimulatory
effects of ScLL and ArtinM leading to increase levels of IFN-γ,
IL-6, TNF, IL-12, and IL-10 have been described for experimental
designs set up in vaccination protocols in murine models
(Afonso-Cardoso et al., 2007; Cardoso et al., 2011). Here, we
are demonstrating for the first time the cytokine production
profile, induced by T. gondii infected mice and treated with
ScLL and ArtinM. Taken into account that it is necessary new
treatment alternatives for toxoplasmosis, due to the limitations
of the current protocols, as their toxic effect and development of
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FIGURE 4 | Effects of sulfadiazine and lectin treatments in the levels of IL-2 (A), IL-4 (B), IFN-γ (C), IL-10 (D), IL-6 (E), TNF (F), and IL-17 (G) cytokines in
serum samples from C57BL/6 mice. Results are expressed as mean ± SD of the cytokine levels in pg/mL. Statistically significances were determined by comparison
of the values obtained in the infected and treated groups with non-treated and non-infected mice. Statistical test was performed using One-way ANOVA and Tukey’s
multiple comparison post-test. *Indicates significant differences (P < 0.05).
parasites resistance (Antczak et al., 2016), the treatment exploring
the immunostimulatory ability of lectins could be considered a
rational alternative, since it is based on the induction of defense
mechanisms of the host against T. gondii infection.
Following the cytokine analysis, it was investigated in the
present study the parasite burden in brain tissues of treated
mice, using quantitative PCR (qPCR) to detect specific T. gondii
DNA. As expected, the highest parasite load was observed in
non-treated mice. The parasite burden did not show significantly
difference between mice treated with sulfadiazine or lectins,
revealing the potential ability of lectins in parasite control.
Sulfadiazine is effective for toxoplasmosis treatment, however, it
has harmful effects to the organism. Currently, toxoplasmosis is
still treated with the synergistic combination of sulfadiazine and
pyrimethamine or triple sulfonamides, which cause bonemarrow
damage, in addition to the potential life-threatening allergic
reactions. For these reasons, alternative drugs as treatment
options, including azithromycin, clarithromycin, dapsone, and
artemisinin, have been studied for toxoplasmosis treatment, but
an extensive number of side effects still persists (Araujo et al.,
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 7 November 2016 | Volume 6 | Article 164
Souza et al. ScLL and ArtinM Lectins for Treatment of Toxoplasmosis
FIGURE 5 | Parasite burden in the brain tissues from treated mice after
30 days of infection with T. gondii ME-29 strain and analyzed by
quantitative real-time PCR. Statistical significances were calculated by
comparison the parasitic DNA values among the treated and non-treated
groups of mice. Statistical test was performed using One-way ANOVA and
Tukey’s multiple comparison post-test. *Indicates significant differences (P <
0.05).
FIGURE 6 | Survival curve of C57BL/6 mice after infection with T. gondii
ME49 strain. Animals were treated with ScLL, ArtinM, ScLL plus ArtinM, or
sulfadiazine during 6 days, one time a day. As control, animals were infected
with the same strain, but treated with phosphate-buffered saline (PBS) only.
The survival curves were compared using the Log-rank Mantel-Cox test.
Values of P < 0.05 were considered statistically significant. *Indicates
significant differences (P < 0.05).
1992a,b; Bosch-Driessen et al., 2002; D’Angelo et al., 2009;
de Oliveira et al., 2009; Yan et al., 2013; Rostkowska et al.,
2016). Thus, it is necessary to investigate alternative approaches
to find efficient and well-tolerated therapeutic agents against
T. gondii infection. In the current study, it was demonstrated that
treatment protocols using ScLL or ArtinM plus ScLL were able
to reduce parasite burden for C57BL/6 mice recently infected by
ME49 strain of T. gondii without side effects.
It has been extensively described in the literature that C57BL/6
mice are highly susceptible to infection by T. gondii, as they
are not able to efficiently control the acute phase of infection,
presenting high rates of mortality (Sánchez et al., 2015). In the
present study, it was observed a significant protective effect of
ScLL and ArtinM treatments in mice orally infected by ME49
strain of the parasite. In fact, when compared to non-treated
group of animals, high percentages of treated animals survived
during the acute phase of T. gondii infection. Regarding the
different experimental groups, C57BL/6 mice treated with ScLL
alone or ScLL plus ArtinM presented survival rates of 100 and
80%, respectively, in contrast with non-treated animals, which
presented significant lower survival rate.
Altogether, the results obtained in present study indicate
important immunostimulatory effects of ScLL and ArtinM that
was able to control T. gondii infection. Further studies will
be necessary to evaluate different protocols to optimize the
efficacy of ScLL and ArtinM lectins on this protozoan infection,
particularly those carry out with different parasite genotypes.
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